Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach

Journal of Medicinal Chemistry

Volumn 45, Issue 13, 2002, Pages 2675-2684

  Terp, Gitte Elgaard ^a   Cruciani, Gabriele ^b   Christensen, Inge Thøger ^c   Jørgensen, Flemming Steen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF PERUGIA   (Italy)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; ION; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; STROMELYSIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANALYTIC METHOD; ARTICLE; DRUG DESIGN; DRUG SELECTIVITY; ELECTROCHEMISTRY; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME INHIBITOR INTERACTION; INHIBITION KINETICS; MOLECULAR INTERACTION; MOLECULAR PROBE; MOLECULAR RECOGNITION; PROTEIN DOMAIN; PROTEIN FAMILY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; CATALYTIC DOMAIN; MATRIX METALLOPROTEINASES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEASE INHIBITORS; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037142342     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0109053     Document Type: Article

References (56)

1. Matrix metalloproteinase degradation of extracellular matrix: Biological consequences
2. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1
3. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor
4. High resolution structure of the N-terminal domain of tissue inhibitor of metalloproteinases-2 and characterization of its interaction site with matrix metalloproteinase-3
5. Three-dimensional structure of human tissue inhibitor of metalloproteinases-2 at 2.1 Å resolution
6. Computational sequence analysis of matrix metalloproteinases
7. On the size of the active site in proteases. I. Papain
8. Matrix metalloproteinases: Structures, evolution, and diversification
9. Comparative modeling methods: Application to the family of the mammalian serine proteases
10. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase Inhibitors
11. Affinity and selectivity of matrix metalloproteinase inhibitors: A chemometrical study from the perspective of ligands and proteins
12. Structural studies of matrix metalloproteinases
13. Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket
14. Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity
15. Potent and selective inhibitors of gelatinase-A 1. Hydroxamic acid derivatives
16. Potent and selective inhibitors of gelatinase-A 2. Carboxylic and phosphonic acid derivatives
17. Phosphinic acid inhibitors of matrix metallopreteinases
18. Cyclic peptides with a phosphinic bond as potent inhibitors of a zinc bacterial collagenase
19. Development of highly potent and selective phosphinic peptide inhibitors of zinc endopeptidase 24-15 using combinatorial chemistry
20. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases
21. GRID/CPCA: A new computational tool to design selective ligands
22. Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis
23. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity
24. Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b
25. Inhibition of matrix metalloproteinases: Structure based design
26. Design and therapeutic application of matrix metalloproteinase inhibitors
27. The SWISS-PROT protein sequence database: Its relevance to human molecular medical research
28. The SWISS-PROT protein sequence data bank and its supplement TrEMBL in 1999
29. SV40-transformed human lung fibroblasts secrete a 92-KDa type IV collagenase which is identical to that secreted by normal human macrophages
30. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages
31. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas
32. CDNA sequence and MRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment
33. Identification and structural and functional characterization of human enamelysin (MMP-20)
34. The protein data bank: A computer-based archival file for macromolecular structures
35. 1.56 Å structure of mature truncated human fibroblast collagenase
36. X-Ray structure of gelatinase A catalytic domain complexed with a hydroxamate inhibitor
37. Inhibition of stromelysin-1 (MMP-3) by P1′-biphenylylethyl carboxyalkyl dipeptides
38. Matrilysin-inhibitor complexes: Common themes among metalloproteases
39. The X-Ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity
40. The CLUSTAL_X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools
41. Structural differences of matrix metalloproteinases. Homology modeling and energy minimization of enzyme-substrate complexes
42. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules
43. New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure
44. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 1. Ligand probe groups with the ability to form two hydrogen bonds
45. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 2. Ligand probe groups with the ability to form more than two hydrogen bonds
46. Atom movements during drug-receptor interactions
47. Sequence specificities of human fibroblast and neutrophil collagenases
48. Comparative sequence specificities of human 72- and 92-KDa gelatinases (type IV collagenases) and PUMP (matrilysin)
49. Substrate specificity of the human matrix metalloproteinase stromelysin and the development of continuous fluorometric assays
50. Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold
51. Structure-based design of a novel, potent, and selective inhibitor for MMP13 utilizing NMR spectroscopy and computer-aided molecular design
52. Recent advances in matrix metalloproteinase inhibitor research
53. Matrix metalloproteinase inhibitors: A structure-activity study
54. Design and synthesis of piperazine-based matrix metalloproteinase inhibitors
55. Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors